Sugi Predict

Sugi Predict / Compounds / SCHEMBL349765

SCHEMBL349765

SCHEMBL349765

O=CNCCc1ccccn1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 1/20 0.59
▸ LMNA P02545 2/20 0.58
▸ TDP1 Q9NUW8 1/20 0.58
▸ ALDH1A1 P00352 2/20 0.58
▸ TAAR1 Q96RJ0 1/20 0.58
▸ ALOX15 P16050 1/20 0.58
▸ CYP1A2 P05177 3/20 0.56
▸ CYP2C19 P33261 1/20 0.56
▸ CYP2D6 P10635 1/20 0.54
▸ CHRM2 P08172 1/20 0.51
▸ HRH1 P35367 1/20 0.50
▸ DPP7 Q9UHL4 1/20 0.47
▸ RAB9A P51151 2/20 0.46
▸ CNR1 P21554 1/20 0.46
▸ NPC1 O15118 1/20 0.45
▸ PKM P14618 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ HSD11B1 P28845 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4779999 0.89 HRH1 (0.54) HRH3LMNATDP1ALDH1A1TAAR1
SCHEMBL1855946 0.89 CHRM2 (0.53) HRH3LMNATDP1ALDH1A1TAAR1
Trifluoroacetic Acid SCHEMBL30453631 0.87 LMNA (0.50) HRH3LMNATDP1ALDH1A1TAAR1
SCHEMBL1921574 0.82 HRH3 (0.70) HRH3LMNATDP1ALDH1A1TAAR1
SCHEMBL399162 0.81 SMN1; SMN2 (0.56) ALDH1A1CHRM2RAB9ANPC1SMN1; SMN2
SCHEMBL23053146 0.80 CYP1A2 (0.69) HRH3LMNATDP1ALDH1A1TAAR1
SCHEMBL12831691 0.80 CYP1A2 (0.58) HRH3LMNATDP1ALDH1A1TAAR1
SCHEMBL349709 0.79 HRH1 (0.55) HRH3LMNATDP1ALDH1A1TAAR1
Ethyne SCHEMBL1922812 0.78 SMN1; SMN2 (0.53) ALDH1A1CHRM2RAB9ANPC1SMN1; SMN2
SCHEMBL1392847 0.77 CHRM2 (0.70) HRH3LMNATDP1ALDH1A1TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240270748-A1 TRICYCLIC HETEROCYCLES MERCK PATENT GMBH (DE) 2024-08-15 — — US claimed
CN-110291068-B Process for the preparation of 2-pyridylethylcarboxamide derivatives 拜耳农作物科学股份公司 2023-04-11 — — CN claimed
EP-3558945-B1 PROCESS FOR THE PREPARATION OF A N-[2-(2-PYRIDINYL)ETHYL]CARBOXAMIDE DERIVATIVE BAYER CROPSCIENCE AG (DE) 2021-05-05 — — EP claimed
US-10807955-B2 Process for the preparation of a 2-pyridylethylcarboxamide derivative BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2020-10-20 — — US claimed
US-20200039937-A1 PROCESS FOR THE PREPARATION OF A 2-PYRIDYLETHYLCARBOXAMIDE DERIVATIVE BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2020-02-06 — — US claimed
EP-3558945-A1 PROCESS FOR THE PREPARATION OF A 2-PYRIDYLETHYLCARBOXAMIDE DERIVATIVE Bayer CropScience Aktiengesellschaft (DE) 2019-10-30 — — EP claimed
WO-2018114484-A1 PROCESS FOR THE PREPARATION OF A 2-PYRIDYLETHYLCARBOXAMIDE DERIVATIVE BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2018-06-28 — — WO claimed
EP-1478653-B1 MACROLIDES WITH ANTIBACTERIAL ACTIVITY BASILEA PHARMACEUTICA AG (CH) 2014-07-02 — — EP claimed
JP-4794570-B2 — — 2011-10-19 — — JP claimed
JP-4603265-B2 — — 2010-12-22 — — JP claimed
EP-1427326-A2 COMBINATION THERAPY FOR THE TREATMENT OF CANCER Sugen, Inc. (US) 2004-06-16 — — EP claimed
US-20040063773-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. & PHARMACIA & UPJOHN CO. 2004-04-01 — — US claimed
US-20030216410-A1 Combination therapy for the treatment of cancer PHARMACIA CORPORATION 2003-11-20 — — US claimed
US-20030212011-A1 Macrolides with antibacterial activity BASILEA PHARMACEUTICA AG (CH) 2003-11-13 — — US claimed
WO-2003072588-A1 MACROLIDES WITH ANTIBACTERIAL ACTIVITY BASILEA PHARMACEUTICA AG (CH) 2003-09-04 — — WO claimed
WO-2003015608-A2 COMBINATION THERAPY FOR THE TREATMENT OF CANCER SUGEN, INC. (US) 2003-02-27 — — WO claimed
EP-1255752-A2 PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS Sugen, Inc. (US) 2002-11-13 — — EP claimed
US-20020156292-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors PHARMACIA & UPJOHN COMPANY LLC 2002-10-24 — — US claimed
WO-2001060814-A2 PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS SUGEN, INC. (US) 2001-08-23 — — WO claimed
US-4716162-A BRAIN FUNCTION SANKYO COMPANY, LIMITED (JP) 1987-12-29 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10807955-B2 Process for the preparation of a 2-pyridylethylcarboxamide derivative CPS1, PLPBP, CYP4F2 HRH3 1220/4885LMNA 1119/4885TDP1 3407/4885
US-20030216410-A1 Combination therapy for the treatment of cancer PTGS2, PTGES2, PTGFR HRH3 2308/4885LMNA 4272/4885TDP1 1224/4885
US-20240270748-A1 TRICYCLIC HETEROCYCLES YAP1, TERF2IP, TEAD1 HRH3 2651/4885LMNA 1870/4885TDP1 760/4885
US-20030212011-A1 Macrolides with antibacterial activity MRPL21, RPS21, MRPS18A HRH3 4642/4885LMNA 2498/4885TDP1 2695/4885
US-20200039937-A1 PROCESS FOR THE PREPARATION OF A 2-PYRIDYLETHYLCARBOXAMIDE DERIVATIVE CPS1, CYP4F2, PLPBP HRH3 1074/4885LMNA 774/4885TDP1 3852/4885
US-20040063773-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors PDPK1, MAP3K20, PLK2 HRH3 4356/4885LMNA 3333/4885TDP1 1009/4885
US-20020156292-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors PDPK1, MAP3K20, PLK2 HRH3 4356/4885LMNA 3333/4885TDP1 1009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.